United Therapeutics Shares Surge 13% Following Q4 Earnings Beat and Strong Guidance

United Therapeutics (UTHR) reported fourth-quarter earnings that exceeded analyst expectations, sparking a significant rally in its stock price. Shares of the biotechnology firm surged by 13% as investors reacted positively to the earnings beat and robust future guidance. A key driver of the performance was the Tyvaso DPI product line, which saw sales jump by 24% during the period. While total revenue figures slightly missed consensus estimates, the strong growth in core products and optimistic outlook outweighed the shortfall. The company's positive forward-looking statements have reinforced investor confidence in its long-term growth trajectory. This double-digit gain reflects the market's focus on profitability and product demand within the competitive biotech sector.